Norton Rose Fulbright advises cannabis company Khiron Life Sciences on acquisition of PharmaDrug Production GmbH

Global law firm Norton Rose Fulbright has advised Canadian cannabis company Khiron Life Sciences on the acquisition of all shares in Germany's PharmaDrug Production GmbH, a German subsidiary of Canada's PharmaDrug Inc. The purchase agreement was signed at the end of May. The transaction is still subject to approval by the German Federal Ministry of Economics and Climate Protection (BMWK).

Khiron Life Sciences Corp. based in Vancouver, Canada, is a vertically integrated medical cannabis company operating primarily in Latin America and Europe. Khiron Life Sciences has its own medical clinics and uses its telemedicine platform to promote the prescription of medical cannabis worldwide.

PharmaDrug Production GmbH in Rostock, Germany, has been a wholesaler of pharmaceuticals and active pharmaceutical ingredients worldwide for more than 30 years. The company mainly imports cannabis of the highest pharmaceutical quality.

The seller Pharmadrug Inc. is a Canadian-based pharmaceutical company focused on the research, development and commercialization of controlled substances and medicines such as psychedelics, cannabis and naturally derived approved drugs.

The Norton Rose Fulbright team was led by Frankfurt partner Nils Rahlf (Corporate/M&A). He was supported by Senior Associate Dr. Ariane Theissen and Associate André Hartmann (both Corporate/M&A, Frankfurt), Partner Tino Duttiné and Senior Associate Sarah Heufelder (both Tax, Frankfurt), Partner Claudia Posluschny and Associate Olivia Reinke (both Labor Law, Munich), Counsel Manuel Merling (IP, Frankfurt), Partner Dr. Maren Stölting and Associate Matthias Kemnitzer (both Real Estate, Munich) and Partner Dr. Tim Schaper and Associate Melina Rohrbach (both Antitrust, Merger/Foreign Direct Investment Control, Hamburg).